In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sophiris Bio Inc.

www.sophirisbio.com

Latest From Sophiris Bio Inc.

Sophiris Will Start Phase III For Topsalysin In Prostate Cancer Despite Mixed Data Package

Emphasizing solid results for the first administration of topsalysin in patients with localized prostate cancer, the firm is sticking with Phase III plans for one dose despite final Phase IIb data showing no clinical benefit from a second dose. Sophiris’ share price tumbled on the news.

Cancer Clinical Trials

Dark Cloud Lifts On Sophiris Bio's Localized Prostate Cancer Injectable Topsalysin

Phase IIb study death after intratumoral injection was unrelated to study drug, San Diego-based start-up says.

Safety Research & Development

Pipeline Watch: Phase III Trials Initiated For AMT-061, RP-G28 And APL-2

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals

Patient Death Obscures Efficacy Success For Sophiris’ Intratumoral Prostate Cancer Therapy

The bad outweighed the good for Sophiris on a day in which it unveiled promising Phase IIb data for topsalysin, but also took a huge stock hit with news of a patient death in the trial.

Clinical Trials Drug Safety
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Gynecological, Urological
  • Alias(es)
  • Protox Therapeutics Inc.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sophiris Bio Inc.
  • Senior Management
  • Randall E Woods, Pres. & CEO
    Peter T Slover , CFO
    Allison Hulme, PhD, Head, R&D & COO
  • Contact Info
  • Sophiris Bio Inc.
    Phone: (858) 777-1760
    1258 Prospect St.
    La Jolla, CA 92037
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register